Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease
about
Proteome analysis of human substantia nigra in Parkinson's diseaseLC/MS analysis of cardiolipins in substantia nigra and plasma of rotenone-treated rats: implication for mitochondrial dysfunction in Parkinson's diseaseOxidative damage to mitochondrial complex I due to peroxynitrite: identification of reactive tyrosines by mass spectrometryThe role of oxidative stress in Parkinson's diseaseAutophagy, mitochondria and oxidative stress: cross-talk and redox signallingCellular interplay between neurons and glia: toward a comprehensive mechanism for excitotoxic neuronal loss in neurodegenerationNeuroprotective and Therapeutic Strategies against Parkinson's Disease: Recent PerspectivesRedox Imbalance and Viral Infections in Neurodegenerative DiseasesDysregulation of glutathione homeostasis in neurodegenerative diseasesThe role of free radicals in the aging brain and Parkinson's Disease: convergence and parallelismMechanistic Details of Glutathione Biosynthesis Revealed by Crystal Structures of Saccharomyces cerevisiae Glutamate Cysteine LigaseSerotonin 1A Receptors on Astrocytes as a Potential Target for the Treatment of Parkinson's DiseaseThe utility of N,N-biotinyl glutathione disulfide in the study of protein S-glutathiolationA study of neurologic symptoms on exposure to organophosphate pesticides in the children of agricultural workersDopamine reduction in the substantia nigra of Parkinson's disease patients confirmed by in vivo magnetic resonance spectroscopic imagingThe high-affinity D2/D3 agonist D512 protects PC12 cells from 6-OHDA-induced apoptotic cell death and rescues dopaminergic neurons in the MPTP mouse model of Parkinson's diseaseIntegration of a precolumn fluorogenic reaction, separation, and detection of reduced glutathione.Iron contributes to the formation of catechol isoquinolines and oxidative toxicity induced by overdose dopamine in dopaminergic SH-SY5Y cells.Oxidative inactivation of mitochondrial aconitase results in iron and H2O2-mediated neurotoxicity in rat primary mesencephalic cultures.Caenorhabditis elegans: a model to investigate oxidative stress and metal dyshomeostasis in Parkinson's diseasePhase IIb Study of Intranasal Glutathione in Parkinson's DiseaseMultiple antioxidants in the prevention and treatment of Parkinson's disease.Central nervous system uptake of intranasal glutathione in Parkinson's disease.NRF2 activation restores disease related metabolic deficiencies in olfactory neurosphere-derived cells from patients with sporadic Parkinson's diseaseOxidative pathology and AQP4 mRNA expression in patients of Parkinson's disease in Tamil NaduGenome-wide association for sensitivity to chronic oxidative stress in Drosophila melanogasterNeocortex and allocortex respond differentially to cellular stress in vitro and aging in vivoNeuroprotective effect of EGb761® and low-dose whole-body γ-irradiation in a rat model of Parkinson's disease.To eat or not to eat: neuronal metabolism, mitophagy, and Parkinson's disease.Synergy between glutathione peroxidase-1 and astrocytic growth factors suppresses free radical generation and protects dopaminergic neurons against 6-hydroxydopamine.The many roads to mitochondrial dysfunction in neuroimmune and neuropsychiatric disordersThe crucial role of metal ions in neurodegeneration: the basis for a promising therapeutic strategy.The roles of redox enzymes in Parkinson's disease: Focus on glutaredoxin.Recent advances on the neuroprotective potential of antioxidants in experimental models of Parkinson's disease.Requirement for cGMP in nerve cell death caused by glutathione depletion.Regulation of antioxidant metabolism by translation initiation factor 2alpha.NADPH oxidase 1 mediates α-synucleinopathy in Parkinson's disease.Phosphatidylcholine-specific phospholipase C regulates glutamate-induced nerve cell death.Role of oxidative stress in refractory epilepsy: evidence in patients and experimental models.Mitochondrial dysfunction and oxidative stress in Parkinson's disease and monogenic parkinsonism.
P2860
Q21245637-11D277F3-B87E-4C64-BFBB-927BAE9C567EQ23923990-759DBBD9-2E2E-4FE8-A955-52301DA81CE8Q24307861-313F68E6-540D-4C36-B924-3685CB2E5B96Q24307946-D5E9F76A-928E-4294-A56D-DABB45A4910EQ24608960-8707A650-564A-4367-B2CD-42D60ECEB68DQ24654460-AD06AE98-6679-4108-A7A2-ACEDAA04B8ADQ26747508-B08024F0-A58B-4400-8AE0-2C508D207F96Q26750630-BE009A62-B88B-49F7-A3D6-03363A7C5056Q26822726-B4EC41F0-0582-4B12-A614-24C4EBE9D6EDQ26852148-F8114AB2-1FC0-4DDC-934E-76C01B3D22F2Q27657285-03848D61-5CA3-492F-BD8D-D27B92F4C416Q28079379-2B70E94F-92E8-4DE1-956C-E22366EC95D4Q28276933-82EA48ED-1185-4413-A95B-F5228D51DCC6Q28384842-0D1E0331-4B25-42C5-BE59-BD4543A156F1Q28538468-0669B3B8-57F4-4822-B2AA-0F58FF79F23EQ28543195-6EB7F38F-4A73-466E-995E-69C9D18CBBB7Q30430795-41E6DFE9-8EBF-4B86-AB91-A0DC274FAFF6Q33337387-1C2DE8C4-FE04-450E-B4A3-D8E4FB041D7BQ33504558-7707220B-3876-4F82-9144-4128DFF0FEF2Q33658107-F6220AF6-676F-4FD1-B331-7C8AFA33AE0CQ33708918-C116C0A1-4412-4609-9800-3ABF67D9DA84Q33746725-3AE43632-C82E-407D-95C7-B38F3F6DFFA9Q33917288-72E36109-1467-4176-BADC-EAF7631156F4Q33958143-8AB1B592-8961-458A-B8E9-71844920B64DQ33979208-F35F2DA7-D64C-4B16-A209-5411AFCC5413Q34310363-2458D14F-BE10-40B4-9397-6F7D36BBC189Q34639246-03024FC7-5528-4FF5-BF67-70F64877CE52Q34733383-87507B5B-1ED2-4935-8DBB-96653187EFC0Q34805897-A6DA0D9B-6295-41D9-A45C-90D1A5B74AC8Q34976266-94363959-192F-4785-98BB-DF76ABDB4FFCQ35246024-8FF5F289-2CDB-4F5E-9074-339C68E7EFCBQ35545150-91331D74-64AA-4D81-B1D7-762EC5E8E260Q35761021-EE7CB7E9-1C03-4BF4-B89E-70210518FDB0Q36202527-B8528111-DB3F-4F10-A9BA-EB4FFDE3EAC4Q36275021-E689E171-645A-4CDC-ADD1-064E07781E0EQ36379914-24A51BE6-963C-437B-B50C-6297A24E2F2BQ36408665-ECEF9CD6-97B0-47A4-9AD4-7CACC262C0EBQ36508125-25D34AC7-A8EE-44BA-9A0A-065BD744BA33Q36590070-46DB850E-539C-4155-80DD-68B33CE0D069Q36590693-15DB8E47-8075-4ECC-8913-FE39DD868646
P2860
Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease
description
1992 nî lūn-bûn
@nan
1992 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1992 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
name
Reduced and oxidized glutathio ...... ients with Parkinson's disease
@ast
Reduced and oxidized glutathio ...... ients with Parkinson's disease
@en
Reduced and oxidized glutathio ...... ients with Parkinson's disease
@nl
type
label
Reduced and oxidized glutathio ...... ients with Parkinson's disease
@ast
Reduced and oxidized glutathio ...... ients with Parkinson's disease
@en
Reduced and oxidized glutathio ...... ients with Parkinson's disease
@nl
prefLabel
Reduced and oxidized glutathio ...... ients with Parkinson's disease
@ast
Reduced and oxidized glutathio ...... ients with Parkinson's disease
@en
Reduced and oxidized glutathio ...... ients with Parkinson's disease
@nl
P2093
P921
P3181
P1433
P1476
Reduced and oxidized glutathio ...... ients with Parkinson's disease
@en
P2093
P304
P3181
P356
10.1016/0304-3940(92)90355-B
P407
P577
1992-08-17T00:00:00Z